MALARONE Drug Patent Profile

When do Malarone patents expire, and what generic alternatives are available?

Malarone is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in MALARONE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Malarone

A generic version of MALARONE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12^th, 2011.

Summary for MALARONE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MALARONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	MALARONE	atovaquone; proguanil hydrochloride	TABLET;ORAL	021078-001	Jul 14, 2000	AB	RX	Yes	Yes
Glaxosmithkline	MALARONE PEDIATRIC	atovaquone; proguanil hydrochloride	TABLET;ORAL	021078-002	Jul 14, 2000	AB	RX	Yes	No

International Patents for MALARONE

See the table below for patents covering MALARONE around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	313225
Bulgaria	62595
Israel	107755	Kit and pharmaceutical compositions comprising a combination of 2-¬4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone and proguanil for the treatment and prophylaxis of parasitic infections
United Kingdom	9224739
Netherlands	950002

Supplementary Protection Certificates for MALARONE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0123238	SPC/GB95/004	United Kingdom		PRODUCT NAME: ATOVAQUONE OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTERED: LU 0458/94/08/0741 19940803; UK 0003/0337 19940823
0123238	95C0009	Belgium		PRODUCT NAME: ATOVAQUONUM; NATIONAL REGISTRTION NO/DATE: 251 IS 151 F 3 19950710; FIRST REGISTRATION: LU 0458/94/08/0741 19940803

Investment Scenario and Fundamentals Analysis for Malarone (Atovaquone and Proguanil)

Last updated: February 20, 2026

Overview

Malarone, marketed by GlaxoSmithKline (GSK) under the active ingredients atovaquone and proguanil, is a prophylactic and treatment medication for malaria. The drug benefits from a high efficacy profile, favorable safety record, and a broad market footprint, especially among travelers and military sectors.

Market Position and Revenue Potential

Malarone's global market was valued at approximately $600 million in 2022, with an expected compound annual growth rate (CAGR) of around 5% through 2027. Factors supporting growth include increasing traveler mobility, expanding malaria-endemic regions, and resistance management strategies.

Market Segmentation

Segment	Distribution & Usage	Market Share (2022)	Growth Drivers
Traveler prophylaxis	Commercial travelers, tourist markets	65%	Rising international travel, COVID-19 recovery
Malaria treatment	Military, endemic regions, travelers	35%	Resistance management, increasing endemicity

Revenue Breakdown

Geography	Share of 2022 Revenue	Key Drivers
North America	45%	High traveler volume, military contracts
Europe	25%	Travel markets, expatriates
Emerging markets	20%	Malaria endemic regions, increasing healthcare access
Rest of World	10%	Military and travel use

Competitive Landscape

The main competitors include doxycycline, mefloquine, chloroquine (resistance concerns), and newer combination therapies such as Tafenoquine. Malarone’s advantages over these include a lower side effect profile, less neuropsychiatric adverse effects, and simplified dosing.

Competitor	Efficacy	Side Effects	Usage Restrictions
Doxycycline	High	Photosensitivity, gastrointestinal	Daily use, contraindicated in pregnancy
Mefloquine	Moderate	Neuropsychiatric effects	Weekly dosing, caution in psychiatric history
Tafenoquine	High	Contraindicated in G6PD deficiency	Single-dose regimen, requires testing

Patent and Regulatory Status

GSK's patent for Malarone expired in key markets by 2025, opening potential for generic entries. The drug holds FDA approval since 1999 and EMA approval since 2000. New formulations, combinations, or expanded indications may face regulatory hurdles but can extend market exclusivity or create new revenue streams.

R&D and Pipeline Considerations

No major new formulations or indications for Malarone have been reported recently. However, research into resistance mechanisms and combination therapies continues. Market shifts toward novel malaria treatments could impact future demand.

Strategic Opportunities and Risks

Opportunities

• Expansion into endemic regions with unmet needs.
• Development of fixed-dose combinations for broader indications.
• Increased military procurement and travel medicine markets.

Risks

• Patent expiry leading to generic competition.
• Resistance development diminishing efficacy.
• Regulatory delays for new formulations or indications.
• Market saturation in high-income regions.

Financial and Investment Outlook

GSK's portfolio relies on mature products like Malarone. Post-generic expiration, revenues may decline without new innovations. Investors should monitor patent litigation, pipeline progress, competitive threats, and geopolitical considerations influencing malaria-endemic regions.

Key Financial Indicators	2022 Data	Trends & Implications
Revenue	$600 million	Stable with slow growth, risks from generics
Patent expiry	2025	Potential revenue erosion post-expiration
R&D investment	Not disclosed	Focused on resistance and new delivery platforms

Summary

Malarone remains a solid asset with steady income attributed to its efficacy, safety, and market penetration. Its future growth hinges on patent management, resistance evolution, and regional market expansion. The upcoming patent expiry in 2025 presents a noteworthy risk; however, ongoing research and potential new formulations could offset revenue decline.

Key Takeaways

• Malarone accounts for a significant share in the global malaria treatment and prophylaxis market, valued at approximately $600 million in 2022.
• The drug’s competitive edge stems from efficacy, safety, and ease of dosing compared to alternatives.
• Patent expiration in 2025 could lead to generic competition, impacting revenue.
• Growth opportunities exist in endemic regions and military sectors but face challenges from resistance and market saturation.
• Strategic positioning depends on innovation, patent strategies, and regional expansion.

FAQs

1. What is the primary market for Malarone?
   Prophylaxis among travelers and malaria treatment in endemic regions.

2. When does GSK's patent for Malarone expire?
   Expiration is expected in 2025 during key markets.

3. How does Malarone compare to other malaria drugs?
   It offers a better safety profile and simpler dosing but faces competition from generics and resistance concerns.

4. What are the main risks for investors in Malarone?
   Patent expiry, generic competition, resistance development, and regulatory delays.

5. Are there any emerging therapies that threaten Malarone’s market?
   Yes, drugs like Tafenoquine and other combination therapies are under development or approved, targeting resistance and simplified regimens.

---

References

[1] MarketResearch.com. (2022). Global Malaria Drugs Market Analysis.[2] GSK. (2022). Malarone Product Information and Regulatory Status.[3] WHO. (2021). Malaria Policy Advisory Group Recommendations.[4] U.S. Food and Drug Administration. (2022). Approved Drugs Database.